Fig. 5: DCK-inactivated PDAC cells are sensitive to mitochondrial complex I and BCL2 inhibitors. | Cell Death & Disease

Fig. 5: DCK-inactivated PDAC cells are sensitive to mitochondrial complex I and BCL2 inhibitors.

From: Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer

Fig. 5

a Dose–response curve of mitochondrial complex I inhibitor, IACS-010759 (0–3000 nmol/L) in DCK#10 and NT1 cells. Cells were treated with IACS-010759 for 72 h. Data are expressed as mean ± standard deviation from three independent triplicate experiments. b Representative crystal violet staining images demonstrating DCK#10 and NT1 cell viability after IACS-010759 treatment (0–3000 nmol/L). c Immunoblot showing elevated expression of BCL2 protein in DCK#10 cells compared to control NT1 cells. β-actin; a loading control. d RT-qPCR revealing anti-apoptotic gene expression, BCL2, in control NT1 and DCK#10 cells. e Dose-response curve of a BCL2 inhibitor, venetoclax (0–30 µmol/L) in DCK knockout (DCK#10) and control NT1 cells. Cells were treated with venetoclax for 72 h. Data are expressed as mean ± standard deviation from three independent triplicate experiments. *P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page